Browse TNFRSF1A

Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Golgi apparatus membrane Single-pass type I membrane protein Secreted Note=A secreted form is produced through proteolytic processing.; SUBCELLULAR LOCATION: Isoform 4: Secreted. Note=Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.
Domain PF00531 Death domain
PF00020 TNFR/NGFR cysteine-rich region
Function

Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.

> Gene Ontology
 
Biological Process GO:0001885 endothelial cell development
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002064 epithelial cell development
GO:0002237 response to molecule of bacterial origin
GO:0003158 endothelium development
GO:0006631 fatty acid metabolic process
GO:0006643 membrane lipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006672 ceramide metabolic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0007009 plasma membrane organization
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009612 response to mechanical stimulus
GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0030148 sphingolipid biosynthetic process
GO:0030856 regulation of epithelial cell differentiation
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033559 unsaturated fatty acid metabolic process
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034612 response to tumor necrosis factor
GO:0042508 tyrosine phosphorylation of Stat1 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042510 regulation of tyrosine phosphorylation of Stat1 protein
GO:0042511 positive regulation of tyrosine phosphorylation of Stat1 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042742 defense response to bacterium
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0045834 positive regulation of lipid metabolic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046467 membrane lipid biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0046889 positive regulation of lipid biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0060759 regulation of response to cytokine stimulus
GO:0061028 establishment of endothelial barrier
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071496 cellular response to external stimulus
GO:0071550 death-inducing signaling complex assembly
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090153 regulation of sphingolipid biosynthetic process
GO:0090154 positive regulation of sphingolipid biosynthetic process
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1901550 regulation of endothelial cell development
GO:1903140 regulation of establishment of endothelial barrier
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1905038 regulation of membrane lipid metabolic process
GO:1990778 protein localization to cell periphery
GO:2000303 regulation of ceramide biosynthetic process
GO:2000304 positive regulation of ceramide biosynthetic process
Molecular Function GO:0005031 tumor necrosis factor-activated receptor activity
GO:0005035 death receptor activity
GO:0019955 cytokine binding
GO:0043120 tumor necrosis factor binding
Cellular Component GO:0043235 receptor complex
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04150 mTOR signaling pathway
hsa04210 Apoptosis
hsa04380 Osteoclast differentiation
hsa04668 TNF signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-73887: Death Receptor Signalling
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-5357905: Regulation of TNFR1 signaling
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-75893: TNF signaling
R-HSA-5357956: TNFR1-induced NFkappaB signaling pathway
R-HSA-5357786: TNFR1-induced proapoptotic signaling
R-HSA-5626978: TNFR1-mediated ceramide production
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFRSF1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFRSF1A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26896171MelanomaInhibit immunity (T cell function)In sharp contrast, DN-TNF treatment dramatically decreased IL1α and increased the essential immunoregulatory cytokines IL1β, IL12p70, and IL17 in the peripheral blood of MCA-injected mice. In addition, MDSC accumulation, STAT3 phosphorylation, and immunosuppression in MCA-injected mice were prevented by DN-TNF treatment, TNFR2-Fc treatment, and/or gene deletion of TNF or TNFR1, but not deletion of TNFR2.
25977337MelanomaInhibit immunity (infiltration)Collectively, our observations indicate that TNF-R1-dependent TNF signaling impairs tumor-infiltrating CD8(+) T-cell accumulation and may serve as a putative target to favor CD8(+) T-cell-dependent immune response in melanoma.
29273790MelanomaInhibit immunity (T cell function); immunotherapy targetHerein, our results indicate that TNF or TNFR1 blockade synergizes with anti-PD-1 on anti-cancer immune responses towards solid cancers.
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFRSF1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFRSF1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3450.193
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8210.776
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0160.993
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0670.849
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.020.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1250.968
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0050.992
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0830.963
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0890.964
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5430.792
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.260.688
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2390.000533
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFRSF1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFRSF1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFRSF1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFRSF1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFRSF1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFRSF1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFRSF1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFRSF1A
Nametumor necrosis factor receptor superfamily, member 1A
Aliases TNF-R; TNFAR; TNFR60; TNF-R-I; CD120a; TNF-R55; TNFR1; FPF; MS5; TNFR1-d2; TNFR55; p55-R; TNF-R1; TNF-RI; TN ......
Chromosomal Location12p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFRSF1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TNFRSF1A.
ID Name Drug Type Targets #Targets
DB035076-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-OneSmall MoleculeTNFRSF1A1
DB11626TasonerminBiotechTNFRSF1A, TNFRSF1B2